BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004

Reuters12-03

Dec 3 (Reuters) - Sutro Biopharma Inc STRO.O:

SUTRO BIOPHARMA ANNOUNCES FIRST COHORT OF PATIENTS DOSED IN PHASE 1 TRIAL OF STRO-004, A NEXT-GENERATION TISSUE FACTOR ADC, IN TF-EXPRESSING SOLID TUMORS
SUTRO BIOPHARMA INC - INITIAL CLINICAL DATA EXPECTED MID-2026

Source text: ID:nGNX4Pq1fN

Further company coverage: STRO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588049311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588049311","market":"fut","top_or_hot":-1,"title":"BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004</title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a> <span>STRO.O</span>:</p><ul><li><p>SUTRO BIOPHARMA ANNOUNCES FIRST <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF PATIENTS DOSED IN PHASE 1 TRIAL OF STRO-004, A NEXT-GENERATION TISSUE FACTOR ADC, IN TF-EXPRESSING SOLID TUMORS</p></li><li><p>SUTRO BIOPHARMA INC - INITIAL CLINICAL DATA EXPECTED MID-2026</p></li></ul><p>Source text: <span>ID:nGNX4Pq1fN</span></p><p>Further company coverage: <span>STRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004</title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a> <span>STRO.O</span>:</p><ul><li><p>SUTRO BIOPHARMA ANNOUNCES FIRST <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF PATIENTS DOSED IN PHASE 1 TRIAL OF STRO-004, A NEXT-GENERATION TISSUE FACTOR ADC, IN TF-EXPRESSING SOLID TUMORS</p></li><li><p>SUTRO BIOPHARMA INC - INITIAL CLINICAL DATA EXPECTED MID-2026</p></li></ul><p>Source text: <span>ID:nGNX4Pq1fN</span></p><p>Further company coverage: <span>STRO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUARTQDN:1","article_id":"2588049311","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588049311","pubTimestamp":1764767100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004Dec 3 (Reuters) - Sutro Biopharma Inc STRO.O:SUTRO BIOPHARMA ANNOUNCES FIRST COHORT OF PATIENTS DOSED IN PHAS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","STRO":"Sutro Biopharma Inc"},"translate_title":"简介-Sutro Biopharma宣布STRO-004 1期试验中第一批患者接受给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STRO":0.9},"content_text":"BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004Dec 3 (Reuters) - Sutro Biopharma Inc STRO.O:SUTRO BIOPHARMA ANNOUNCES FIRST COHORT OF PATIENTS DOSED IN PHASE 1 TRIAL OF STRO-004, A NEXT-GENERATION TISSUE FACTOR ADC, IN TF-EXPRESSING SOLID TUMORSSUTRO BIOPHARMA INC - INITIAL CLINICAL DATA EXPECTED MID-2026Source text: ID:nGNX4Pq1fNFurther company coverage: STRO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588049311","isCrawlerRequest":true}